Agilent Ventures has taken part in a Novo Growth-led round that brought the precision medicine technology developer's overall funding to more than $120m.
Pharmaceutical firm Novo has led a $70m series C round for US-based DNA analysis technology developer Mission Bio that included laboratory equipment and diagnostics services provider Agilent Technologies.
Cota Capital, Mayfield Fund and Soleus Capital also contributed to the round, while Novo and Agilent participated through their Novo Growth and Agilent Ventures units respectively.
The round took the company’s total funding to more than $120m, it said, and Robert Ghenchev, head of Novo Growth, has joined its board of directors.
…
